EGFR and colorectal carcinoma: Though this in vitro data is limited, along with the genomic data described in the two studies, it suggests that CRC cells may develop resistance to chemotherapy and anti-EGFR through nongenomic mechanisms compared to later-lines when anti-EGFR is given as a single agent.